We frequently get asked what cleanroom class an IVD consumable line "needs." It's a fair question, but it's usually the wrong starting point. For an implantable device, particulate and sterility drive the design. For a lateral flow strip or a microfluidic cartridge feeding a nucleic-acid assay, the contamination that quietly kills your product often isn't a particle you can count — it's a nuclease you can't.
This piece walks through how to select an ISO 14644 class for diagnostic consumables, which contamination risks actually drive that decision for lateral flow and microfluidic formats, and how to document environmental monitoring (EM) data so it holds up under the QMSR. It's part of LSO's broader work on scaling diagnostic consumable manufacturing.
What ISO 14644 Actually Classifies — and What It Doesn't
ISO 14644-1:2015 classifies cleanroom and clean-zone air cleanliness by airborne particle concentration, spanning ISO Class 1 through ISO Class 9 across particle sizes from 0.1 µm to 5 µm (ISO 14644-1:2015). The 2015 revision changed how the largest particles are handled, excluding ≥5 µm counts from defining ISO Class 5 because of statistical-sampling limitations at low concentrations (ISO 14644-1:2015). If you carried an older classification report into a new validation, that's a detail worth checking.
Two things matter here. First, the standard is industry-agnostic — it does not prescribe a class for IVD versus implantable devices, and it says nothing about biological, bioburden, or nuclease contamination (ISO 14644-1:2015). Second, classification is not monitoring. ISO 14644-2:2015 governs ongoing monitoring and is a separate exercise from the classification testing in 14644-1 (ISO 14644-2:2015). A clean classification report from last quarter does not demonstrate that your room held its state between testing intervals. Auditors know the difference, and so should your EM program.
Why IVD Class Selection Diverges From Implantables
For a sterile implantable, the logic runs straight from particulate burden and bioburden control toward a sterile barrier and a terminal sterilization step. The cleanroom class is chosen to keep particulate and microbial load low going into sterilization.
IVD consumables rarely follow that path. Many lateral flow strips and microfluidic cartridges are not terminally sterilized, and "sterile" is often not the relevant attribute at all. What matters is whether the consumable performs at the variability margin of the assay — and for nucleic-acid formats, that margin is set by molecular contamination, not microbes.
So the class-selection question shifts. Instead of asking "how clean for sterility," you ask: what contamination would change the test result, and at what threshold? ISO 13485:2016 Clause 6.4 frames this directly — you must control work-environment conditions needed to prevent product contamination wherever those conditions could adversely affect product quality (ISO 13485:2016 Clause 6.4). The clause states the obligation; it does not hand you a class. You justify the class from product risk.
In our experience, that justification leads IVD consumable lines to a particulate class that is often less aggressive than an implantable line — but paired with biological and molecular controls that an implantable line may not need at all.
The Contamination Risks That Actually Drive Design
Particulate
Particulate still matters. A particle bridging a microfluidic channel or sitting on a reaction membrane is a defect. ISO 14644 gives you the framework to set and verify a particulate class. But for most IVD consumables, particulate is the floor, not the ceiling, of your contamination strategy.
Bioburden
Bioburden control protects assay performance and shelf stability. Microbial load and the metabolic byproducts that come with it can interfere with reagents and degrade consumables over time. This is a biological risk that airborne particle counts do not capture — which is why a particle-only EM program leaves a gap on an IVD line.
RNase and DNase
For any consumable feeding a nucleic-acid amplification assay, nucleases are the contamination that should keep you up at night. RNases and DNases are environmentally ubiquitous, stable, and capable of degrading target nucleic acids or assay reagents at concentrations far below anything a particle counter registers.
The good news is that nuclease contamination is measurable and controllable. A peer-reviewed study of low-cost microfluidic chips for LAMP amplification found that ethanol rinses combined with UV-C radiation reduced RNase contamination up to tenfold on the chips (ScienceDirect S2666053925000724). That's a bench-scale R&D result on specific chip materials and reagents — decontamination efficacy is material- and reagent-specific, and you should not assume the same chemistry or efficacy transfers to every format (ScienceDirect S2666053925000724). But it makes the larger point: nuclease control during assembly is a real pathway you can design around, not an act of faith.
Before a team starts blazing a new trail for nuclease control, the tried-and-true path is to treat it as its own contamination stream in your risk analysis — with its own controls (material handling, glove discipline, dedicated consumables, validated decontamination) and its own evidence. It will not show up in your ISO 14644 particle data, and it cannot be inferred from it.
Documenting Environmental Monitoring Under the QMSR
As of February 2, 2026, the FDA Quality Management System Regulation (QMSR) amended 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, replacing most of the legacy Quality System Regulation prose (FDA QMSR). Practically, that means the documentation expectations for your EM program now flow through ISO 13485:2016 clauses, not the old subpart text. The FDA did add requirements clarifying certain ISO 13485 concepts to avoid inconsistencies with other FDA rules, and combination-product quality-system expectations continue under 21 CFR Part 4 (FDA QMSR FAQ) — relevant if your consumable ships as part of a combination product.
Three clauses carry most of the weight for an IVD EM program.
Work environment (Clause 6.4). You document the contamination controls you've determined are necessary — particulate class, bioburden limits, nuclease handling — and the rationale tying each to product quality. The clause requires the control where conditions could adversely affect product; it does not dictate the numbers, so your risk justification is the document that matters (ISO 13485:2016 Clause 6.4).
Process validation (Clause 7.5.6). Any process whose output cannot be fully verified by later inspection and testing must be validated (ISO 13485:2016 Clause 7.5.6). For cleanroom-dependent consumables, this links your environmental controls to documented process validation — you cannot inspect nuclease contamination out of a finished cartridge, so the environment and decontamination steps that prevent it sit inside your validation scope. Recent FDA thinking on QMS submissions has gone as far as recommending applicants include example validation plans and protocols for environmental or contamination controls, which is a useful signal of the evidence reviewers expect.
Records (Clauses 8.2.6 and 4.2.5). Records of monitoring, measurement, and acceptance activities must be maintained to demonstrate product conformity (ISO 13485:2016 Clause 8.2.6, Clause 4.2.5). For EM, that means the data — particle counts, bioburden results, nuclease checks — needs to be retained and traceable to the lots it covers. The clauses set the obligation but leave retention periods, sampling frequency, and the exact linkage format to your QMS to define and justify.
The practical translation: build your EM program so every released lot can be tied back to the environmental evidence in force when it was made, across all the contamination streams that matter for that product — not just the particle data ISO 14644 produces. That linkage is what an auditor follows, and it's the gap a particle-only program leaves open on an IVD line.
The Short Version
Don't start with a class number. Start with the contamination that would change your test result. For lateral flow and microfluidic consumables, that's usually bioburden and nucleases at least as much as particulate — and those risks demand controls and EM evidence that ISO 14644 classification, on its own, never captures. Select your class from that risk analysis, monitor against 14644-2 between classifications, and document the whole chain through the ISO 13485:2016 clauses the QMSR now points to.